Trial Profile
A Real World Study for Cost-Effectiveness of Crizotinib Versus Chemotherapy as First-Line Treatment of ALK Positive Advanced Non Small Cell Lung Cancer
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 11 Oct 2018
Price :
$35
*
At a glance
- Drugs Crizotinib (Primary)
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- 11 Oct 2018 New trial record
- 26 Sep 2018 Cost-Effectiveness results of Crizotinib Versus Chemotherapy in NSCLC were presented at the 19th World Conference on Lung Cancer